Case number 1:23-cv-00031
Amgen Inc. et al v. MSN Laboratories Private Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 9, 2023 | 13 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (mdb) (Entered: 11/09/2023) (1) |
| Feb 10, 2023 | 11 | STIPULATION of Voluntary Dismissal without Prejudice and Proposed Consolidation Order by Amgen Inc., KAI Pharmaceuticals, Inc.. (Clark, Cameron) (Entered: 02/10/2023) (3) |
| Feb 10, 2023 | 12 | SO ORDERED re (11 in 1:23-cv-00031-MN, 154 in 1:21-cv-00662-MN) Stipulation of Voluntary Dismissal without Prejudice and Proposed Consolidation Order. Party MSN Life Sciences Private Limited terminated. Attorney Kenneth Laurence Dorsney terminated as to this Defendant. Signed by Judge Maryellen Noreika on 2/10/2023. (dlw) (Entered: 02/10/2023) (3) |
| Feb 10, 2023 | N/A | Case associated with lead case: Create association to 1:21-cv-00662-MN. (dlw) (Entered: 02/10/2023) (0) |
| Feb 3, 2023 | 10 | STIPULATION TO EXTEND TIME for MSN Defendants to answer, move or otherwise respond to the Complaint to February 10, 2023 - filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Dorsney, Kenneth) (Entered: 02/03/2023) (2) |
| Feb 3, 2023 | N/A | SO ORDERED re 10 STIPULATION TO EXTEND TIME for MSN Defendants to answer, move or otherwise respond to the Complaint to February 10, 2023 (Set/Reset Answer Deadlines: MSN Laboratories Private Limited answer due 2/10/2023; MSN Life Sciences Private Limited answer due 2/10/2023; MSN Pharmaceuticals Inc. answer due 2/10/2023). ORDERED by Judge Maryellen Noreika on 2/3/2023. (dlw) (Entered: 02/03/2023) (0) |
| Jan 18, 2023 | N/A | Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb) (Entered: 01/18/2023) (0) |
| Jan 13, 2023 | 7 | SUMMONS Returned Executed by Amgen Inc., KAI Pharmaceuticals, Inc..MSN Laboratories Private Limited served on 1/13/2023, answer due 2/3/2023. (Clark, Cameron) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 8 | SUMMONS Returned Executed by Amgen Inc., KAI Pharmaceuticals, Inc..MSN Life Sciences Private Limited served on 1/13/2023, answer due 2/3/2023. (Clark, Cameron) (Entered: 01/13/2023) (2) |
| Jan 13, 2023 | 9 | SUMMONS Returned Executed by Amgen Inc., KAI Pharmaceuticals, Inc..MSN Pharmaceuticals Inc. served on 1/13/2023, answer due 2/3/2023. (Clark, Cameron) (Entered: 01/13/2023) (2) |
| Jan 12, 2023 | 1 | COMPLAINT filed against MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc. ( Filing fee $ 402, receipt number ADEDC-4042573.) - filed by Amgen Inc., KAI Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Related Cases, # 3 Civil Cover Sheet)(twk) (Entered: 01/12/2023) (Main Document) (13) |
| Jan 12, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) (Entered: 01/12/2023) (3) |
| Jan 12, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: November 30, 2022. Date of Expiration of Patent: June 27, 2034. Thirty Month Stay Deadline: 8/7/2024. (twk) (Entered: 01/12/2023) (2) |
| Jan 12, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,162,500. (twk) (Entered: 01/12/2023) (1) |
| Jan 12, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Amgen Inc. for KAI Pharmaceuticals, Inc. filed by Amgen Inc., KAI Pharmaceuticals, Inc. (twk) (Entered: 01/12/2023) (2) |
| Jan 12, 2023 | 6 | Summons Issued as to MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc. on 1/12/2023. (Attachments: # 1 Summons Issued, # 2 Summons Issued)(twk) (Entered: 01/12/2023) (Main Document) (2) |
| Jan 12, 2023 | 1 | COMPLAINT filed against MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc. ( Filing fee $ 402, receipt number ADEDC-4042573.) - filed by Amgen Inc., KAI Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Related Cases, # 3 Civil Cover Sheet)(twk) (Entered: 01/12/2023) (Exhibit A) (30) |
| Jan 12, 2023 | 1 | COMPLAINT filed against MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc. ( Filing fee $ 402, receipt number ADEDC-4042573.) - filed by Amgen Inc., KAI Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Related Cases, # 3 Civil Cover Sheet)(twk) (Entered: 01/12/2023) (Related Cases) (2) |
| Jan 12, 2023 | 1 | COMPLAINT filed against MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc. ( Filing fee $ 402, receipt number ADEDC-4042573.) - filed by Amgen Inc., KAI Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A, # 2 Related Cases, # 3 Civil Cover Sheet)(twk) (Entered: 01/12/2023) (Civil Cover Sheet) (1) |
| Jan 12, 2023 | 6 | Summons Issued as to MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc. on 1/12/2023. (Attachments: # 1 Summons Issued, # 2 Summons Issued)(twk) (Entered: 01/12/2023) (Summons Issued) (2) |
| Jan 12, 2023 | 6 | Summons Issued as to MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc. on 1/12/2023. (Attachments: # 1 Summons Issued, # 2 Summons Issued)(twk) (Entered: 01/12/2023) (Summons Issued) (2) |
